Navigation Links
Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
Date:7/25/2008

- Management to discuss second quarter financial results -

LAVAL, QC, July 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 8 at 8:30 a.m. (ET) to discuss its second quarter 2008 financial results. Labopharm will report its second quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-646-3095 or 1-800-814-4859. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21278611 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
2. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
3. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
4. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
5. Labopharm Reports Results for First Quarter Fiscal 2008
6. Labopharm announces details for first quarter results conference call and annual meeting
7. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
10. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
11. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair ... available to both Snapchat users and those who do not use the app. Dr. Mohebi, ... his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive ...
(Date:5/26/2016)... ... 2016 , ... Eating Recovery Center, Washington (ERC ... brand new child and adolescent residential treatment center on June 1. The 18-bed, ... specialized eating disorder treatment and access to life-saving care. , To celebrate, ERC ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology: